d3 Medicine LLC and Viroclinics Biosciences BV form virology drug development alliance to serve the - Gilde Healthcare

d3 Medicine LLC and Viroclinics Biosciences BV form virology drug development alliance to serve the

July 1, 2014

Strategic alliance to provide services from virology assay development and testing to formulation of accelerated clinical development plans for drugs, biologicals, vaccines and diagnostics

Parsippany, New Jersey, United States and Rotterdam, the Netherlands – d3 Medicine LLC, an expert biopharmaceutical strategic advisory company, and Viroclinics Biosciences BV, a virology service organization, announced today that they have signed a non-exclusive Memorandum of Understanding to provide biopharmaceutical customers with an integrated solution to accelerate the preclinical and clinical development of drugs, biologicals, vaccines and diagnostics targeting viral infectious diseases.

The alliance leverages the strengths of the two companies and will offer services that enable biopharmaceutical customers to accelerate virological investigational agents through preclinical and clinical development to market launch. Viroclinics Biosciences will provide a range of preclinical and clinical diagnostic services, including high throughput serology, virology and molecular assays, phenotyping and genotyping in both translational studies and phase I-IV clinical studies, and clinical trial logistics services.

d3 Medicine will formulate integrated development, clinical pharmacology and translational medicine strategies to fast-track preclinical development and define customised pharmacometric and quantitative pharmacological approaches to improve decision making and accelerate clinical and regulatory development.

“Biopharmaceutical companies now can turn to d3 Medicine and Viroclinics Biosciences to develop and implement their preclinical, clinical and regulatory strategies when developing therapeutics, vaccines and diagnostics for viral infectious diseases,” said Dr Craig Rayner, CEO and co-Founder of d3 Medicine.

“We are delighted to be able to work more formally with the team at d3 Medicine,” said Dr Bob van Gemen, CEO of Viroclinics Biosciences. “They have great credibility in the market and when combined with the unique virology capabilities and expertise of Viroclinics Biosciences, we believe that through our partnership we offer customers the most comprehensive and exciting range of development services available in the virology field. We can support our biopharmaceutical customers with the best virological knowledge available and provide them with integrated and optimally customised development programs and project solutions.”

About d3 Medicine LLC

d3 Medicine is a biopharmaceutical drug development strategic advisory company founded by a group of pharmaceutical company executives with decades of drug development experience. d3 Medicine aims to address the prevailing R&D market failure and to assist in the development of medicines that matter to society, for the people that need them most. It is committed to delivering impactful healthcare solutions through developing and executing value focussed drug development programs, business development strategies and technical due diligence. For more information, visit the website at www.d3medicine.com.

About Viroclinics Biosciences BV

Headquartered in Rotterdam, The Netherlands, Viroclinics Biosciences operates at a global level and is the preferred virology testing laboratory for several of the top 10 biopharmaceutical companies. As a virology service organization, the company performs preclinical studies, serves as a central and reference laboratory for phase I-IV clinical trials including high throughput serology-, virology- and molecular assays, assay development services and clinical trial logistics services, involving global logistic support for clinical sample shipment, cold-chain management of the samples and a 24/7 helpdesk in English and Spanish. For more information visit the website at www.viroclinics.com.

Gilde Healthcare company Volta Medical announces positive results from transatlantic trial on AI-assisted ablation for persistent atrial fibrillation

TAILORED-AF randomized controlled trial (RCT) findings demonstrated superiority in freedom from atrial fibrillation (AF) at 12 months from a tailored cardiac ablation guided by artificial intelligence (AI) when compared to pulmonary vein isolation (PVI) alone....
May 21, 2024

Gilde Healthcare co-leads $100M equity financing in Karius

Karius®, Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding. The round was co-led by Gilde Healthcare, Khosla Ventures and 5AM Ventures, and...
May 2, 2024

Gilde Healthcare company Ablative Solutions demonstrates Significant Reduction in Blood Pressure meeting its primary endpoint in Pivotal Trial

Ablative Solutions, Inc., announced that primary trial results from the TARGET BPI Pivotal Trial, evaluating alcohol-mediated renal denervation with the Peregrine SystemTM Kit, were presented as a Late-Breaking Clinical Trial at the American College of...
April 11, 2024